

Date: December 22, 2009

To: MA.15 Principal Investigators  
MA.15 Principal Clinical Research Associates

From: Lois E. Shepherd, MDCM, Physician Coordinator  
Michael J. Palmer M.Sc., Study Coordinator

Re: **NCIC CTG MA.15**  
**A Phase I/II Study of Docetaxel and Epirubicin as First Line Therapy for Metastatic Breast Cancer**

**\*\* Further to Notice of MA.15 Permanent Closure \*\***

A Final Closure Notice from the Group is posted on the Permanent Trial Closure webpage. MA.15 is included. The link for the letter is <http://www.ctg.queensu.ca/trials/closure.html>

The purpose of this letter is to inform you that we are in the final stages of preparing the MA.15 manuscript. There is the potential for continued querying of MA.15 data, as described in the next paragraph.

Though the trial is permanently closed, previously submitted data may be subject to ongoing querying. Any queries will be completed within the next 2 months. Thus, sites may wish to retain trial files on site rather than archiving, in order to be able to respond in a timely manner. (Note: REB approvals are not generally required for queries regarding data submitted while annual approvals were in place).

Thank you for your continued involvement with MA.15. We appreciate your dedication to this important study and look forward to the completion of the manuscript and its publication.

Should you have any questions in regard to this letter, please do not hesitate to contact Michael Palmer in the Central Office.

cc: Maureen Trudeau, Study Chair  
Dongsheng Tu, Biostatistician  
Karen Gelmon and Timothy J. Whelan, Chairs, Breast Site Committee  
Sue McIndoe, CRA Representative, Breast Site Committee  
Charlene Cruz-Co, Senior CRA, Sanofi-Aventis